Startups
Gameto has created a three-part platform for ovarian therapeutics that will address menopause and assisted fertility.
Founded in 2014 and number 3 on BioSpace’s NextGen Bio “Class of 2022” life science startups to watch, Eikon Therapeutics today closed on a Series B financing worth $517.8 million.
Formerly Esker Therapeutics, a San Francisco-based biotech company, now named Alumis, closed on a $200 million Series B financing round to help advance its precision immunology medicines.
During a season of giving, investors were extra generous to these biotech companies this week.
1E Therapeutics announced $120 million seed funding, a remarkable feat for an early-stage biotech company. The funding is the largest of its kind for an Israeli biotech company.
The Cambridge, Massachusetts-based company has developed an artificial intelligence platform designed to optimize pharmaceutical formulation processes.
Life sciences investors are being anything but shy as the end of 2021 draws near. Here are a few companies that are still seeing cash come in the door as December gets underway.
Tune claims TEMPO can rapidly target and adjust the epigenomic machinery, controlling gene expression and dictating how the DNA will be molded.
The radiopharmaceuticals being developed by Curie are composed of rationally designed conjugates in contrast to delicately chosen biological targets.
The precision medicine company is developing mutant selective and isoform-specific drugs in non-conventional ways for well-known targets in the oncology and autoimmune spaces.
PRESS RELEASES